• Final CEP-1 data confirm tolerability of Veyonda alone and in combination with carboplatin
• Halt in progression of cancer growth in 50% of patients
• Study provides proof-of-concept for well-tolerated chemotherapy with meaningful survival benefit
SYDNEY, November 29, 2018, Noxopharm (ASX:NOX) announces the final results from its Phase 1b CEP-1 trial evaluating its lead immuno-oncology/radio-enhancer drug candidate, Veyonda, in combination with low-dose carboplatin in late-stage metastatic solid cancers.
For further information please download PDF attached:
Download this document
